Menu

All Activities

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information

Featured Activity

Equipping Healthcare Professionals with the Necessary Tools for Improving Care in Ovarian Cancer

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

SHOW SEARCH

Monoclonal Antibody Treatment and Post-exposure Prophylaxis Training for Healthcare Providers

Activity Downloads

To Participate

To participate in this continuing education activity:

  1. Review the activity description and objectives.
  2. View the activity.
  3. Complete the online post-test and activity evaluation.
A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) 

 
 View more SIDPEC Activities 
 

Description

Monoclonal antibody (mAb) therapy has exhibited clinical benefit for treatment of mild-to-moderate COVID-19 in non-hospitalized patients who are at high risk for progression to severe disease. More recently, certain mAbs have been approved for post-exposure prophylaxis (PEP) of COVID-19 in high-risk individuals. Pharmacists in various practice settings have opportunities to impact patient care related to use of mAb in COVID-19. This CE program is intended to educate pharmacists on available mAb therapeutics, highlight their role in treatment and PEP of COVID-19, and provide resources for infusion sites offering mAb to patients. Click here for the latest COVID-19 Monoclonal Antibody Toolkit.
 

Learning Objectives

The target audience for this activity is pharmacists. At the completion of this CE activity the participant will be able to do the following in regard to specific treatments being considered for COVID-19:

  • Recognize key stakeholders and aspects of a monoclonal antibody (mAb) infusion site.
  • Outline clinical characteristics that would make patients appropriate candidates for mAb therapy.
  • Identify resources necessary for mAb preparation and administration.
  • Review clinical data, national guidelines, and drug-specific guidance for available mAb therapeutics.
  • Highlight important considerations of a monoclonal antibody (mAb) infusion site for post-exposure prophylaxis (PEP).
  • Outline clinical characteristics that would make patients appropriate candidates for mAb PEP therapy.
  • Describe drug-specific considerations for mAb PEP therapy.
  • Summarize clinical data, national guidelines, and available resources for mAb therapeutics indicated for PEP.

Faculty

Kristen Zeitler, BS, PharmD, BCPS
Pharmacotherapy Specialist, Infectious Diseases
Tampa General Hospital
Tampa, FL

Accreditation

Release Date: November 17, 2021
Expiration Date: November 17, 2024

Pharmacists

ACPE LogoThis activity is jointly provided by ProCE, LLC and the Society of Infectious Diseases Pharmacists. ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-21-282-H01-P has been assigned to this home-study knowledge-based activity. This activity is approved for 2.0 contact hours (0.2 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure

It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed in this activity. Dr. Zeitler has no relevant commercial or financial relationships to disclose.

Funding

This toolkit was sponsored by an unrestricted medical grant from Regeneron Pharmaceuticals, Inc.

 

The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.